Welcome to our dedicated page for Petvivo Hldgs SEC filings (Ticker: PETV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PetVivo Holdings filings document material events for a Nevada corporation operating through PetVivo Animal Health and PetVivo AI. Recent Form 8-K reports cover subscription agreements, unregistered equity sales, restricted common stock, warrants, unit issuances, and Regulation D exemptions tied to private financing activity.
The filing record also includes Regulation FD investor-presentation exhibits and governance disclosures under Item 5.02, including director resignations and changes in board size. These documents provide formal disclosure around the company’s capital structure, warrant terms, board composition, and public-company reporting status as an emerging growth company.
A.L. Sarroff Fund, LLC, a 10% owner of PetVivo Holdings, Inc., reported a bona fide gift transfer of 200,000 shares of common stock on May 28, 2026. The transfer was recorded at $0.00 per share, and the fund now directly holds 10,252,229 shares. Alan L. Sarroff, as Chief Executive Officer and Managing Member of the fund, is deemed to beneficially own these securities with sole voting and dispositive power.
PetVivo Holdings, Inc. saw its significant shareholder A.L. Sarroff Fund, LLC make an open-market purchase of common stock. On May 22, 2026, the fund bought 250,000 shares at 0.40 per share, increasing its direct holdings to 10,452,229 shares.
Alan L. Sarroff, as Chief Executive Officer and Managing Member of A.L. Sarroff Fund, is deemed to beneficially own these securities and to have sole voting and dispositive power over them. This transaction modestly increases an already large position in the company.
PetVivo Holdings, Inc. reported that its Chief Financial Officer, Garry N. Lowenthal, indirectly acquired 66,421 shares of common stock as a grant of restricted stock. The award was made to a corporation owned by him as compensation for his past performance at an implied price of $0.72 per share.
Following this grant, the filing shows 878,881 shares of common stock held indirectly through the corporation. This is a compensation-related, non-market transaction rather than an open-market purchase or sale.
Lai John reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. reported that a corporation owned by Chief Executive Officer John Lai received a grant of restricted common stock as compensation for his past performance. The award covers 66,421 shares of common stock at a stated value of $0.72 per share.
Following this grant, the corporation associated with Lai holds 2,306,913 shares of PetVivo common stock indirectly. This is a compensation-related stock award rather than an open-market purchase or sale, and reflects additional equity granted to an entity affiliated with the CEO.
Rudelius Robert James reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings director Robert James Rudelius purchased 50,000 shares of restricted common stock in a private sale. On April 15, 2026, he bought these shares from another PetVivo shareholder at $0.40 per share, bringing his direct holdings to 403,392 common shares. He also reports indirect ownership of 21,000 common shares held by a corporation.
PetVivo Holdings, Inc. closed the final tranche of a private equity financing on April 15, 2026, receiving $600,000 and bringing the total investment under a Subscription Agreement to $1,000,000. The Company issued 1,250,000 units at $0.80 per unit, each unit containing one restricted common share and a warrant to buy one common share at $1.10. The warrants are exercisable immediately and expire three years from issuance. The investor also received an option to purchase up to an additional $1,500,000 of equity on similar terms, for up to 1,875,000 more units, which the Company anticipates could be funded on or before June 15, 2026. The transaction was structured as a private placement to an accredited investor under Section 4(a)(2) and Regulation D, and all securities issued are characterized as restricted.
PetVivo Holdings, Inc. entered into a Subscription Agreement for $1,000,000 of equity financing through 1,250,000 units priced at $0.80 per unit. Each unit includes one restricted common share and a warrant to buy one share at $1.10, exercisable immediately and expiring three years from issuance.
The company received $400,000 on March 13, 2026 and expects the remaining $600,000 by April 15, 2026. The investor also received an option to provide an additional $1,500,000 for 1,875,000 more units on the same terms, anticipated by June 30, 2026. The private placement was conducted under Section 4(a)(2) and Regulation D, with the investor representing accredited status, and all securities issued as restricted under Rule 144.
PetVivo Holdings, Inc. disclosed that A.L. Sarroff Fund, LLC, a ten percent owner, made open-market purchases of its common stock. The fund bought a total of 24,033 shares on March 23, 2026, including 23,033 shares at $0.68 and 1,000 shares at $0.7499 per share. Following these transactions, the fund directly holds 10,202,229 common shares, with Alan L. Sarroff deemed to beneficially own and exercise sole voting and dispositive power over these securities.
Rudelius Robert James reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. director Robert James Rudelius received a one-time grant of 35,000 shares of restricted common stock as compensation for prior Board service, valued at $0.74 per share on the grant date. Following this award, he directly holds 353,392 common shares. He also has an additional 21,000 shares reported as indirectly held through a corporation. This Form 4 reflects a compensation-related share grant rather than an open-market purchase or sale.
Ruben Joshua David reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings director Ruben Joshua David reported stock-based compensation grants. He received an aggregate annual grant of 46,332 restricted common shares for Board service, vesting in four installments: 8,832 shares for the pro-rated first quarter and 12,500 shares at the beginning of each subsequent quarter of service.
He also received a one-time grant of 7,500 restricted shares as compensation for prior Board service. Following these awards, he holds 53,832 common shares directly. These are compensation-related grants, not open-market purchases or sales.